on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Files its 2024 Universal Registration Document
Paris, April 8, 2025 - GenSight Biologics, a biopharmaceutical company listed on Euronext, announced the filing of its 2024 universal registration document. This document, submitted to the AMF, includes key information such as the 2024 annual financial report, the management report, the corporate governance report and a description of the share buyback program.
This document is available on the company's website and on the AMF website. GenSight Biologics focuses on gene therapies for neurodegenerative diseases of the retina and central nervous system, using innovative technologies to restore or preserve vision.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news